Table 2.
Diagnostic performance of CLCA2, SPATS2, ST6 GALNAC1 and Adipophilin expressions in differentiation between Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC)
| Marker expression | Histopathological subtype |
Total N=60 |
P | Sensitivity (95% CI) | Specificity (95% CI) | AUC (95% CI) | PPV (95% CI) | NPV (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Squamous |
Adenocarcinoma |
||||||||||||
| N=30 |
N=30 |
||||||||||||
| N | % | N | % | N | % | ||||||||
| CLCA2* | Negative | 5 | 16.70% | 29 | 96.70% | 34 | 56.70% | <0.001 | |||||
| Positive | 25 | 83.30% | 1 | 3.30% | 26 | 43.30% | (65- 94%) 80% |
(82- 99%) 90% |
(0.795 - 0.962) | (78.333% - 99.425%) | (72.211% - 92.829%) | ||
| SPATS2* | Negative | 3 | 10.00% | 29 | 96.70% | 32 | 53.30% | <0.001 | |||||
| Positive | 27 | 90.00% | 1 | 3.30% | 28 | 46.70% | (73- 97%) 85% |
(82- 99%) 94% |
(0.838 - 0.982) | (79.659% - 99.466%) | (76.729% - 96.592%) | ||
| Adipophilin£ | Negative | 27 | 90.00% | 3 | 10.00% | 30 | 50.00% | <0.001 | |||||
| Positive | 3 | 10.00% | 27 | 90.00% | 30 | 50.00% | (62- 96%) 78% |
(73- 97%) 86% |
(0.751 - 0.952) | (65.597% - 94.395%) | (75.899% - 96.258%) | ||
| ST6GALNAC1£ | Negative | 28 | 93.30% | 1 | 3.30% | 29 | 48.30% | <0.001 | |||||
| Positive | 2 | 6.70% | 29 | 96.70% | 31 | 51.70% | (82- 99%) 84% |
(77- 99 %) 89% |
(0.861 - 0.990) | (79.143% - 98.227%) | (80.262% - 99.484%) | ||
| CLCA2, SPATS2, ST6 GALNAC1, and Adipophilin | 100% | 100% | 100% | 100% | 100% | ||||||||